Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 9;51(1):408.
doi: 10.1007/s11033-024-09303-0.

Long-term antigen-specific immune response by an oncolytic adenovirus encoding SP-SA-E7-4-1BBL in HPV-16 cancer model

Alejandra G Martinez-Perez  1 , Rodolfo Garza-Morales  2 , Maria de J Loera-Arias  1 , Sheila A Villa-Cedillo  1 , Aracely Garcia-Garcia  1 , Humberto Rodriguez-Rocha  1 , Orlando E Flores-Maldonado  3 , Jesus Valdes  4 , Jose J Perez-Trujillo  5 , Odila Saucedo-Cardenas  6
Affiliations

Long-term antigen-specific immune response by an oncolytic adenovirus encoding SP-SA-E7-4-1BBL in HPV-16 cancer model

Alejandra G Martinez-Perez et al. Mol Biol Rep. .

Erratum in

Abstract

Background: To describe an oncolytic adenovirus (OAd) encoding SP-SA-E7-4-1BBL that is capable of inducing tumor regression in therapeutic assays. Herein, we tested whether the antitumor effect is given by the induction of a tumor-specific immune response, as well as the minimum dose needed to elicit antitumor protection and monitor the OAd biodistribution over time.

Methods and results: C57BL/6 mice (n = 5) per group were immunized twice with OAds encoding SP-SA-E7-4-1BBL, SA-E7-4-1BBL, or SP-SA-4-1BBL and challenged with TC-1 cancer cells. The DNA construct SP-SA-E7-4-1BBL was employed as a control via biolistic or PBS injection. Groups without tumor development at 47 days were rechallenged with TC-1 cells, and follow-up lasted until day 90. The minimum dose of OAd to induce the antitumor effect was established by immunization using serial dilution doses. The cytometry bead assay and the ELISpot assay were used to evaluate cytokine release in response to ex vivo antigenic stimulation. The distribution profile of the OAd vaccine was evaluated in the different organs by histological, immunohistochemical and qPCR analyses. The OAd SP-SA-E7-4-1BBL-immunized mice did not develop tumors even in a rechallenge. A protective antitumor effect was observed from a dose that is one hundredth of most reports of adenoviral vaccines. Immunization with OAd increases Interferon-gamma-producing cells in response to antigen stimulation. OAd was detected in tumors over time, with significant morphological changes, contrary to nontumor tissues.

Conclusions: The OAd SP-SA-E7-4-1BBL vaccine confers a prophylactic, safe, long-lasting, and antigen-dependent antitumor effect mediated by a Th1 antitumor immune response.

Keywords: Cancer adjuvants; Cancer vaccine; Targeted therapy; Viral vectors.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660 - DOI
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics, 2021. CA: A Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654 - DOI
    1. Sobhani N, Scaggiante B, Morris R et al (2022) Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials. Cancer Treat Rev 109:102429. https://doi.org/10.1016/j.ctrv.2022.102429 - DOI - PubMed - PMC
    1. Raja J, Ludwig JM, Gettinger SN et al (2018) Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 6:140. https://doi.org/10.1186/s40425-018-0458-z - DOI - PubMed - PMC
    1. Kim DW, Cho J-Y (2020) Recent advances in allogeneic CAR-T Cells. Biomolecules 10:263. https://doi.org/10.3390/biom10020263 - DOI - PubMed - PMC

LinkOut - more resources